<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Labriola,L.</style></author><author><style face="normal" font="default" size="100%">Hombrouck,A.</style></author><author><style face="normal" font="default" size="100%">Marechal,C.</style></author><author><style face="normal" font="default" size="100%">Steven Van Gucht</style></author><author><style face="normal" font="default" size="100%">Bernard Brochier</style></author><author><style face="normal" font="default" size="100%">Isabelle Thomas</style></author><author><style face="normal" font="default" size="100%">Jadoul,M.</style></author><author><style face="normal" font="default" size="100%">Goubau,P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients</style></title><secondary-title><style face="normal" font="default" size="100%">Nephrol.Dial.Transplant.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">2009</style></keyword><keyword><style  face="normal" font="default" size="100%">Adjuvants,Immunologic</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged,80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">an</style></keyword><keyword><style  face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibody</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">at</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Comparative Study</style></keyword><keyword><style  face="normal" font="default" size="100%">Control</style></keyword><keyword><style  face="normal" font="default" size="100%">de</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">GM</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemagglutination Inhibition Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">High risk</style></keyword><keyword><style  face="normal" font="default" size="100%">HIGH-RISK</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Increase</style></keyword><keyword><style  face="normal" font="default" size="100%">INFLUENZA</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza A Virus,H1N1 Subtype</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza,Human</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Failure,Chronic</style></keyword><keyword><style  face="normal" font="default" size="100%">LEVEL</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">males</style></keyword><keyword><style  face="normal" font="default" size="100%">method</style></keyword><keyword><style  face="normal" font="default" size="100%">methods</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">observed</style></keyword><keyword><style  face="normal" font="default" size="100%">ON</style></keyword><keyword><style  face="normal" font="default" size="100%">p</style></keyword><keyword><style  face="normal" font="default" size="100%">pandemic</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Renal Dialysis</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">Still</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style  face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1/4/2011</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1428</style></number><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">1424 - 1428</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: The 2009 pandemic of influenza A (H1N1) prompted an urgent worldwide vaccination campaign, especially of high-risk subjects, such as maintenance haemodialysis (HD) patients. Still the immunogenicity of the pandemic A (H1N1) vaccine in HD patients is unknown. METHODS: We prospectively studied the immunogenicity of a monovalent adjuvanted influenza A/California/2009 (H1N1) vaccine (Pandemrix, GSK Biologicals, Rixensart, Belgium) in HD patients and controls. Antibody level was measured using a seroneutralization assay before (D(0)) and 30 days after (D(30)) a single 3.75 mug vaccine dose. Specimens were tested in quadruplicates. Geometric mean (GM) antibody titers were determined in each subject at D(0) and D(30). Seroconversion was defined as an increase in GM titers by a factor 4 or more. RESULTS: Fifty-three adult HD patients [aged 71 +/- 10, 58.5% males, on HD for a median of 38 (3 - 146) months] and 32 control subjects (aged 47.3 +/- 14, 31.3% males) were analyzed. Baseline GM titers were similar in HD patients and controls [7.9 (6.6 - 9.6) vs 10 (6 - 17); p = 0.69]. Seroconversion was observed in 30 (93.8%) controls and 34 (64.2%) HD patients (p = 0.002). In addition, GM titers at D(30) were significantly higher in controls than in HD patients [373 (</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">36552</style></custom1><section><style face="normal" font="default" size="100%">1424</style></section></record></records></xml>